FDA OKs Pluristem production facility, shares jump

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

    The FDA has approved Pluristem Therapeutics' (PSTI +5.9%) request to produce PLacental eXpanded (PLX) cell products at a new manufacturing facility.

    The FDA's authorization adds to that of the Paul-Ehrlich-Institute (PEI) in Germany.

    The plant can produce approximately 150,000 doses of PLX cells a year. (PR)